Work Here?
Overview
Interius BioTherapeutics develops in vivo CAR T cell delivery technology for blood cancers. Its delivery system prompts the patient’s own cells to become CAR T cells inside the body, removing the need for outside-the-body cell manipulation and often avoiding pre-conditioning chemotherapy. This differentiates it from conventional CAR T therapies by offering a simpler, potentially safer single-system approach. The goal is to bring gene-therapy–based, in vivo CAR T treatments to patients with hematologic malignancies and expand the platform to other diseases, while pursuing product development and future sales within a collaborative, inclusive culture.
About Interius BioTherapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$504.4M
Headquarters
Philadelphia, Pennsylvania
Founded
2019
Simplify's Take
What believers are saying
- First patient dosed October 23, 2024, in INVISE Phase 1 trial without CRS or neurotoxicity.
- PEI approved European expansion January 7, 2025, first in vivo CAR trial there.
- Preclinical data show complete B-cell depletion in animal models.
What critics are saying
- Kite Pharma acquisition fails FTC antitrust block by Q1 2026, halting commercialization.
- INT2104 Phase 1 reveals off-target transduction, stopping trial Q3 2025.
- Sana SC291 outperforms INT2104 preclinicals, securing partnerships by mid-2026.
What makes Interius BioTherapeutics unique
- INT2104 generates CAR-T and CAR-NK cells in vivo via CD7-targeted lentiviral vectors.
- Eliminates ex vivo manipulation and preconditioning chemotherapy for single IV infusion.
- Targets CD20-positive B cells for hematologic malignancies without special equipment.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$504.4M
Above
Industry Average
Funded Over
5 Rounds
Growth & Insights and Company News
6 month growth
↓ -12%1 year growth
↑ 15%2 year growth
↑ 15%Gilead regularly strengthens its portfolio through acquisitions of early-stage drugmakers, such as its $350 million agreement to acquire Interius BioTherapeutics in August 2025.
Kite Pharma to acquire Interius BioTherapeutics for $350 million to advance in-vivo CAR T therapies.
Kite, a Gilead Company, announced it will acquire Interius BioTherapeutics for $350 million in cash. The acquisition will integrate Interius's in vivo CAR therapeutic platform into Kite's portfolio, allowing CAR T-cells to be generated directly within patients. The deal is expected to reduce Gilead's 2025 earnings per share by $0.23-$0.25. Closing is subject to regulatory approval. Kite, acquired by Gilead in 2017, leads in CAR T-cell therapy treatments globally.
Now Gilead has embraced the approach in acquiring Interius, which uses engineered viruses to deliver into certain immune cells instructions for cancer-targeting protein receptors.
Interius BioTherapeutics announces regulatory approval to expand Phase 1 Clinical Trial of INT2104 into Europe.
There are no jobs for Interius BioTherapeutics right now.
Find jobs on Simplify and start your career today
About Interius BioTherapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$504.4M
Headquarters
Philadelphia, Pennsylvania
Founded
2019
There are no jobs for Interius BioTherapeutics right now.
Find jobs on Simplify and start your career today